Fluicell logo

Om bolaget Analys Analytikerkommentar Video Textintervju

Fluicell provides research solutions for drug development and 3D bioprinting applications worldwide. The Company also offers solutions for maintaining localized compound delivery in single-cell experiments, thus enabling control of the chemical environment around single intact cells in tissue or cell cultures. Additionally, Fluicell’s strategic focus on tissue-based therapeutics within regenerative medicine and tissue-based disease models for drug development continues to mature. The company was founded in 2012 in Gothenburg, Sweden, and is listed on Nasdaq First North Growth Market since 2018.


Tyvärr kan finansiell information för tillfället ej hämtas på detta bolag.